Home Cart Sign in  
Chemical Structure| 1902123-72-1 Chemical Structure| 1902123-72-1

Structure of GSK2879552 2HCl
CAS No.: 1902123-72-1

Chemical Structure| 1902123-72-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

GSK2879552 2HCl is an orally available, irreversible, inhibitor of lysine specific demethylase 1 (LSD1), with potential antineoplastic activity.

Synonyms: GSK2879552 dihydrochloride

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of GSK2879552 2HCl

CAS No. :1902123-72-1
Formula : C23H30Cl2N2O2
M.W : 437.40
SMILES Code : O=C(O)C1=CC=C(CN2CCC(CN[C@H]3[C@H](C4=CC=CC=C4)C3)CC2)C=C1.[H]Cl.[H]Cl
Synonyms :
GSK2879552 dihydrochloride
MDL No. :MFCD30481342

Safety of GSK2879552 2HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Related Pathways of GSK2879552 2HCl

epigenetics

Isoform Comparison

Biological Activity

Target
  • KDM1

    LSD1, Ki:1.7 μM

In Vitro:

Cell Line
Concentration Treated Time Description References
P53/R26-Zeb2tg/tg mouse T-ALL cells 10.39 nM 4 days Zeb2-overexpressing mouse T-ALL cells were highly sensitive to the KDM1A inhibitor GSK2879552, undergoing apoptosis 48 hours after treatment initiation PMC5783288
LOUCY human T-ALL cells 112.91 nM 12 days Human T-ALL cells with high ZEB2 expression (LOUCY) were sensitive to the KDM1A inhibitor GSK2879552 PMC5783288
RAW264.7 cells 500 µM 24 hours To investigate the effect of GSK2879552 on macrophage polarization, the results showed that GSK2879552 only targets the FAD domain and cannot disrupt the LSD1-CoREST complex, thus failing to effectively induce M1-like macrophage polarization. PMC6582666
M1 macrophages 5 μM 24 hours To investigate the effect of GSK2879552 on the expression of oxidative stress and pro-inflaμMatory genes in M1 macrophages. The results showed that GSK2879552 significantly reduced the transcript levels of Nox1, Nox2, Nox4, p22phox, MCP-1, and TNFα in M1 macrophages. PMC9774905
Bone marrow-derived macrophages (BμMs) 0.5, 1, 2 µM 4 days To assess the effect of LSD1 inhibitors on osteoclast differentiation, results showed that LSD1 inhibitors prevent osteoclast differentiation in a dose-dependent manner. PMC9967819
MOLM-13 cells 1.9±0.9 nM 6 days To assess the effect of GSK2879552 on cell proliferation, results showed inhibition of cell proliferation PMC6545850
THP-1 cells 23±4 nM 1 day To assess the effect of GSK2879552 on cell differentiation, results showed increased CD11b expression PMC6545850
hPSC-derived cortical neurons 1 µM 7 days GSK2879552, in combination with other compounds, promotes neuronal maturation, increasing synaptic density, electrophysiological function, and transcriptomic profiles PMC11348887
hPSC-derived cortical neurons 5 µM 7 days GSK2879552, as an LSD1 inhibitor, demonstrated the ability to promote neuronal maturation in the screening assay PMC11348887

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice MC38-OVA tumor model Intraperitoneal injection 60 mg/kg Five times a week for 4 weeks GSK2879552 restored the Id2 knockout phenotype, increased the abundance of Slamf6+Tim-3?Texprog cells, and rectified the decrease in the level of Tcf1 in Id2-deleted CD8+T cells PMC10902300
Mice NSG mice Oral 50 mg/kg 5 days a week for 4 weeks KDM1A inhibitor GSK2879552 significantly delayed leukemia formation in Zeb2-overexpressing mouse T-ALL cells PMC5783288
Mice ZEB2TgETP-ALL tumour model Oral 1.5 mg/kg body weight Daily To evaluate the effect of GSK2879552 in combination with Ruxolitinib on the ZEB2TgETP-ALL tumour model, the results showed that the combination therapy significantly reduced splenomegaly and improved mouse survival. PMC9712096
Mice ApoE-/- mice Intraperitoneal injection 1200 ppm Daily, for 2 months To investigate the effect of GSK2879552 on atherosclerotic lesion formation in ApoE-/- mice. The results showed that GSK2879552 significantly reduced the formation of atherosclerotic lesions and decreased the expression levels of Nox1, Nox2, Nox4, and p22phox in the aorta. PMC9774905
Mice 4T1 TNBC breast cancer model Intraperitoneal injection 5 mg/kg 4 weeks To investigate the effect of LSD1 inhibitors on reinvigorating CD8+ T cell subsets PMC7309504
Mice Ovariectomy-induced osteoporosis model Intraperitoneal injection 1200 ppm From PND 24 to 3 months To assess the effect of GSK2879552 on ovariectomy-induced osteoporosis, results showed that GSK2879552 slightly restored OVX-induced cortical bone loss. PMC9967819

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.29mL

0.46mL

0.23mL

11.43mL

2.29mL

1.14mL

22.86mL

4.57mL

2.29mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories